# A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults

> **NCT04271592** · PHASE1 · COMPLETED · sponsor: **Assembly Biosciences** · enrollment: 120 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** ABI-H3733 Liquid Oral Dosage Form
- **DRUG:** ABI-H3733 Solid Oral Dosage Form
- **DRUG:** Placebo to ABI-H3733 Liquid Oral Dosage Form
- **DRUG:** Placebo to ABI-H3733 Solid Oral Dosage Form

## Key facts

- **NCT ID:** NCT04271592
- **Lead sponsor:** Assembly Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-17
- **Primary completion:** 2020-11-03
- **Final completion:** 2021-01-14
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04271592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04271592, "A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04271592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*